All News

Tezepelumab significantly reduced exacerbations that required hospitalization or an emergency department visit in a new analysis of patients with moderate-to-severe, uncontrolled asthma.

Nearly two-thirds of persons aged younger than 50 years who had an acute ischemic stroke had obesity in a study presented at the 2022 International Stroke Conference.

Atrial fibrillation-related ischemic stroke may be a factor in hospital deaths among over 50% of older adults, suggests new findings presented at the International Stroke Conference.

Prior authorization-related delays in care have led to serious patient outcomes, including hospitalization, disability, even death, said one-third of physicians surveyed.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Higher daily step counts by women aged ≥65 years was associated with reduced risk for incident diabetes, an effect that was modified by the level of stepping intensity.

These 42 factors that affect blood glucose are listed in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Is virtual reality a viable option for chronic pain management? A new scoping review suggests it has potential. Here, key findings for primary care.

Tirzepatide at 3 different doses significantly improved glycemic control and promoted weight loss when added to titrated insulin in patients with type 2 diabetes.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

New research highlights several key risk factors that are likely to accelerate the progression from asthma to COPD, including older age and prior tobacco use.

Optimal use of biologic therapy for severe uncontrolled asthma rests on understanding of the disease itself. Try this quick quiz to test your knowledge.

Use of SGLT2 inhibitor and GLP-1 RA therapy in patients with type 2 diabetes appears to confer hepatic protection when compared with use of DPP-4 inhibitors.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

New data from the phase 3 NAVIGATOR trial found tezepelumab treatment reduced inflammatory biomarkers of severe, uncontrolled asthma in as little as 2 weeks.

Greatest improvements in A1c, %TIR, and other glycemic parameters were seen in patients treated with ≤1 medication, in another challenge to current payer restrictions.

Integrating NAFLD as a diabetes complication to be addressed during routine cycles of care could reduce barriers to a NAFLD pathway in primary care, agreed focus group participants.

NYU endocrinologist Brian Levy, MD, offers perspective on keeping the transition from basal insulin to multiple daily injections as simple as possible for patient and provider.